Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Imugene Limited (IUGNF)
OTHER OTC:IUGNF
Imugene Limited (IUGNF) Stock Price & Analysis
22 Followers
IUGNF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.02 - $0.11
Previous Close$0.07
Volume1.00K
Average Volume (3M)122.05K
Market Cap
$507.70M
Enterprise Value$440.06M
Total Cash (Recent Filing)AU$99.89M
Total Debt (Recent Filing)AU$673.43K
Price to Earnings (P/E)-7.7
Beta0.93
Next Earnings
Aug 30, 2024EPS Estimate
>-$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding7,319,810,809
10 Day Avg. Volume98,378
30 Day Avg. Volume122,045
Standard Deviation0.69
R-Squared0.12
Alpha0.09
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Imugene Limited News
PremiumCompany Announcements
Imugene Director’s Shareholding Adjustment
PremiumCompany Announcements
Imugene Limited Issues New Equity Securities
PremiumCompany Announcements
Imugene Limited Announces Investor Webinar
PremiumCompany Announcements
Imugene Partners with Kincell for Growth and Savings
PremiumCompany Announcements
Imugene Limited Announces Securities Cessation
PremiumCompany Announcements
Imugene Limited Issues New Employee Incentives
PremiumCompany Announcements
Imugene Advances Promising Cancer Therapy TrialPremiumCompany Announcements
Imugene’s Breakthroughs Offer Cancer Treatment HopeOptions Prices
Currently, No data available
---
Ownership Overview
9.91% Insiders
2.70% Mutual Funds
2.97% Other Institutional Investors
84.42% Public Companies and
Individual Investors
IUGNF FAQ
What was Imugene Limited’s price range in the past 12 months?
Imugene Limited lowest stock price was $0.02 and its highest was $0.11 in the past 12 months.
What is Imugene Limited’s market cap?
Currently, no data Available
When is Imugene Limited’s upcoming earnings report date?
Imugene Limited’s upcoming earnings report date is Aug 30, 2024 which is in 127 days.
How were Imugene Limited’s earnings last quarter?
Imugene Limited released its earnings results on Feb 28, 2024. The company reported -$0.007 earnings per share for the quarter, missing the consensus estimate of $0 by -$0.007.
Is Imugene Limited overvalued?
According to Wall Street analysts Imugene Limited’s price is currently Overvalued.
Does Imugene Limited pay dividends?
Imugene Limited does not currently pay dividends.
What is Imugene Limited’s EPS estimate?
Imugene Limited’s EPS estimate is >-$0.01.
How many shares outstanding does Imugene Limited have?
Imugene Limited has 7,319,811,000 shares outstanding.
What happened to Imugene Limited’s price movement after its last earnings report?
Imugene Limited reported an EPS of -$0.007 in its last earnings report, missing expectations of $0. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Imugene Limited?
Currently, no hedge funds are holding shares in IUGNF
---
Imugene Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
IUGNF Sentiment 93%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-33.64%
12-Months-Change
Fundamentals
Return on Equity
-42.91%
Trailing 12-Months
Asset Growth
9.08%
Trailing 12-Months
Company Description
Imugene Limited
Imugene Ltd specializes is a clinical-stage immuno-oncology company. Its product includes HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being Research, Development, and Commercialisation of oncolytic immunotherapies.
---
Technical Analysis
---